Please login to the form below
ozanimod
This page shows the latest ozanimod news and features for those working in and with pharma, biotech and healthcare.
BMS and Celgene announce $74bn merger
s slip-ups, including the botched filing of MS candidate ozanimod a year ago. ... It also TYK2 and ozanimod in immunology and inflammation, and two more in haematology: luspatercept and fedratinib.
Latest news
-
Celgene to launch five new products through to 2020
The five blockbusters-in-waiting are multiple sclerosis therapy ozanimod – which has been delayed by the FDA’s refusal to accept the company’s regulatory filing earlier this year – fedratinib for
-
Novartis files for approval of MS drug in EU, US
Another potential rival – Celgene’s ozanimod – hit the buffers after the FDA refused to accept the company’s regulatory filing earlier this year.
-
Daily Brief: Brexit reshuffle brings new health minister, Celgene thalassemia success, Wellcome ready to leap into future
The news is very welcome for Celgene, which has suffered numerous setbacks in recent months, including the FDA refusing to accept the filing of ozanimod in February.
-
Daily Brief: Gottlieb sets out cell and gene pathway, NICE says no to Chiesi ultra-rare treatment and more
Smith looked to have paid the price for some costly slip-ups in recent months, most notably the FDA’s refused to review Celgene’s multiple sclerosis drug, ozanimod.
-
Morning brief: Gilead partners with Verily, Roche expands 4DMT partnership and more
new drugs, multiple sclerosis candidate ozanimod - and all because the company had failed to provide adequate non-clinical and clinical pharmacology data in its dossier.
More from news
Approximately 2 fully matching, plus 9 partially matching documents found.
Latest Intelligence
-
Pharma deals in July 2015
Celgene believes Receptos's ozanimod in phase III for ulcerative colitis could reach peak sales of $4bn to $6bn per year. ... Receptos / Celgene. Company acquisition. Ozanimod in Phase 3 for auto-immune disease.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
-
Medical Writer
-
Salary TBC
-
Associate Director
-
£75, 000-90, 000
- Account Manager / Senior Account Manager
-
35, 000-40, 000
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
- Senior Account Director development role to Business Director, H...
-
Excellent package
-
Account Manager / Account Director
-
Competative
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
-
Account Director
-
Competitive Salary Offered
- Global Business Development Director – Health Education
-
excellent commission
-
Account Director, Medical Education
-
Salary TBC
-
Senior Medical Writer
-
Salary TBC
-
Business Director
-
Competitive Salary Offered
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
-
Senior Account Manager
-
Competitive Salary Offered
Subscribe to our email news alerts
- Europe closer to biosimilar rule change, despite fierce resistance from pharma
- FDA expecting boom in cell and gene therapies
- Moving annual total (MAT)
- AZ’s Sean Bohen to exit after business overhaul; report
- FDA moves into crisis mode as shutdown drags on
- Lucid Group prepare for a transformative year with the appointment of a new Director of Corporate Development
PMHub
3 Monkeys Zeno
3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...
Latest intelligence
- NHS regional footprints
- What to expect from 2019...
- Not another weight-loss ad
- Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
- China’s clinical trial shake-up
- As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Quick links
Infographics
